CTLA4 and neoplasm: The situation becomes more complicated in case of target antigens expressed on Treg lymphocytes (anti-CTLA-4) or on tumor cells (anti-PD-L1, anti-CD47), where it could be of high interest to have IgG equipped with effector functions and possibly boosted IgG1 to kill the cells expressing the targeted antigen.